Changes at the top of commercial units for Gilead and BMS

Christopher Boerner was promoted to lead commercial at BMS, and Laura Hamill joined Gilead from Amgen to head up its commercial operations.

from Most popular articles from Medical Marketing and Media https://ift.tt/2N1SlSu

Five things for pharma marketers to know: Wednesday, August 29, 2018

Gilead appoints new commercial lead; U.K. bans online ad for contraception app; Pfizer petitions the FDA to clarify biosimilar communications.

from Most popular articles from Medical Marketing and Media https://ift.tt/2wnJ3GU

Experts split on impact of drug price hike freezes

Some of the world's most powerful pharmaceutical companies backed down on planned price increases following a new transparency law in California and social media hectoring from President Donald Trump.

from Most popular articles from Medical Marketing and Media https://ift.tt/2BPEeeB

Healthcare's own 'Undoing Project'

What two connoisseurs of human error taught the world about the mind's inner workings has implications for healthcare marketing.

from Most popular articles from Medical Marketing and Media https://ift.tt/2OWhhIn

Five things for pharma marketers to know: Tuesday, August 28, 2018

Gilead's CAR-T cell therapy ruled too expensive in the U.K.; Experts mixed on impact of drug price hike freezes; Women turn to wearables for fertility tracking

from Most popular articles from Medical Marketing and Media https://ift.tt/2MVsNXc

Five things for pharma marketers to know: Monday, August 27, 2018

Pfizer's drug tafamidis reduces risk of death; Lilly Diabetes pulls its sponsorship of Daly's car; FDA investigates electronic cigarette maker Juul.

from Most popular articles from Medical Marketing and Media https://ift.tt/2PJhcsT

The highs and lows of cannabis branding

Chase Design Group's John Tanner shares what he thinks brands can do to spice things up when it comes to marketing around marijuana.

from Most popular articles from Medical Marketing and Media https://ift.tt/2MCaoze

Got name? A peek into the sometimes bizarre land of pharma brand-naming

As more medications are approved, pharma companies are being pushed farther afield into a land of bizarre — but hopefully still memorable and vaguely meaningful — drug names.

from Most popular articles from Medical Marketing and Media https://ift.tt/2BLcfgb

Behind the Exact Sciences/Pfizer Cologuard co-promotion deal

The companies plan to make the most of favorable market access conditions for the at-home colon cancer screening test.

from Most popular articles from Medical Marketing and Media https://ift.tt/2P3Kvov

Five things for pharma marketers to know: Friday, August 24, 2018

White House proposes rule for drug prices in DTC ads; FDA to study impact of side-effects warnings in drug ads; FDA approves Shire's potential blockbuster HAE treatment.

from Most popular articles from Medical Marketing and Media https://ift.tt/2MsJJVr

Pfizer lawsuit could clear path for biosimilars

Biosimilars have only been in the market for three years, but they have struggled to compete with their branded equivalents.

from Most popular articles from Medical Marketing and Media https://ift.tt/2P1qjUf

Five things for pharma marketers to know: Thursday, August 23, 2018

Trump's conflicting policies on PBMs confuse the industry; Pfizer strikes deal to co-promote Cologuard; Tech company develops microchip for dementia patients.

from Most popular articles from Medical Marketing and Media https://ift.tt/2MN2nGX

David Gideon, medical media icon and industry stalwart, dies at 75

For Gideon, honoring those who helped build the medical ad industry became a labor of love.

from Most popular articles from Medical Marketing and Media https://ift.tt/2MS4vKo

FCB Health looks to the future of content with Studio Rx launch

Studio Rx will offer services in experiential media like virtual and augmented reality, 360-degree video, and installations.

from Most popular articles from Medical Marketing and Media https://ift.tt/2Lgxjuf

Five things for pharma marketers to know: Wednesday, August 21, 2018

FDA extends EpiPen expiration dates; GE Ventures senior managing director departs; Facebook launches MRI research project.

from Most popular articles from Medical Marketing and Media https://ift.tt/2w6cFs7

Five things for pharma marketers to know: Tuesday, August 21, 2018

FDA gives Keytruda new real-time approval; AstraZeneca headquarters construction boondoggle; Lack of sleep costs U.S. economy hundreds of billions per year.

from Most popular articles from Medical Marketing and Media https://ift.tt/2MCnpbj

Novo Nordisk's Ozempic takes on Lilly's Trulicity in DTC showdown

The two diabetes rivals air competing TV spots as they compete for GLP-1 supremacy.

from Most popular articles from Medical Marketing and Media https://ift.tt/2PpZqdE

Five things for pharma marketers to know: Monday, August 20, 2018

Azar says HHS can eliminate rebates; States pass measures to stop drug price increases; 'Poor oversight' blamed for California sitting on cash to treat mentally ill.

from Most popular articles from Medical Marketing and Media https://ift.tt/2MlZygB

Evoke Group rebrands, reorganizes subsidiary agencies

The renamed Evoke will replace the individual agency network with six areas of focus.

from Most popular articles from Medical Marketing and Media https://ift.tt/2PpMzIG

Five things for pharma marketers to know: Friday, August 17, 2018

Purdue Pharma taps financial restructuring firm; White House wants opioid-production cut; NYU to make med school free.

from Most popular articles from Medical Marketing and Media https://ift.tt/2MzvfSM